AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04018573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Support Film
Description: Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance.
Study NCT04018573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Support Film
Description: Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance.
Study NCT03300973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sling surgery
Description: transoburator vaginal tape ,inside out procedure under spinal anathesia
Study NCT04218045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic single anastomosis sleeve ileal bypass
Description: a simple loop gastro-ileal bypass is added to the sleeve procedure.
Study NCT04218045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Conventional sleeve gastrectomy using endoscopic stapler
Study NCT04288609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intendu
Description: Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
Study NCT04288609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil cognitive remediation training
Description: Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
Study NCT02883998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Physical Therapy
Description: traditional outpatient physical therapy which occurs at a physical therapy office
Study NCT02883998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Base Physical Therapy
Description: Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
Study NCT03090828 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: app-based therapeutic education
Description: Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.
Study NCT03090828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced app-based therapeutic education
Description: Patients in the enhanced app group will also have access to a social network. (forum, chat room)
Study NCT03392285 — intervention group
Intervention type: DEVICE
Intervention: Internal fixation or hip arthroplasty
Description: Patients treated according to the routine at the orthopedic department with screw fixation of an undisplayed femoral neck fracture or hip arthroplasty for a displaced femoral neck fracture.
Study NCT01174290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Description: IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy.
Study NCT01174290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W 0.2mL IV q6h~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy.
Study NCT03026985 — intervention group
Intervention type: OTHER
Intervention: Observational cohort
Description: Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
Study NCT04065945 — intervention group
Intervention type: OTHER
Intervention: Completion questionnaires/providing biological samples
Description: Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
Study NCT04261426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: IVIG 0.5g/kg/d for 5 days
Study NCT04261426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care
Study NCT04261426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care
Study NCT04277182 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: burn wound dressing
Description: 1. st. group: It will be considered as a control group and rats will not be treated.~2. nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~3. rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~4. th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~5. th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~6. th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days.
Study NCT04277182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burn wound dressing
Description: 1. st. group: It will be considered as a control group and rats will not be treated.~2. nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~3. rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~4. th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~5. th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~6. th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days.
Study NCT04277182 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: burn wound dressing
Description: 1. st. group: It will be considered as a control group and rats will not be treated.~2. nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~3. rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~4. th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~5. th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~6. th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days.
Study NCT00156637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team-Based Quality Improvement Intervention
Description: Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
Study NCT03540056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: We use ultrasound to measure the PRF and the testicular volumes.
Study NCT01004211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrow band imaging transurethral resection
Description: Transurethral resection of bladder lesion by mean of narrow band imaging
Study NCT01004211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transurethral resection
Description: Transurethral resection of bladder lesion by mean of standard white light
Study NCT00156637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opinion Leader Intervention
Description: Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
Study NCT00156637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team Based Quality Improvement
Description: Intervention to increase appropriate use of clozapine through a team based quality intervention.
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Description: Capsule containing 200 mg FTC, taken once daily, for 96 weeks
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Description: Tablet containing 300 mg TDF, taken once daily, for 96 weeks
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz (EFV)
Description: Tablet containing 600 mg EFV, taken once daily, for 96 weeks
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Tablet containing 600 mg EFV, taken once daily, for 96 weeks
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF/EFV
Description: Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
Study NCT00112047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine/zidovudine
Description: Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
Study NCT01986673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Sildenafil Cream (SST-6006)
Description: 5 % Sildenafil Cream
Study NCT01986673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sildenafil 50 mg
Description: Oral Sildenafil 50 mg
Study NCT00559611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound
Description: A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
Study NCT00559611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediastinoscopy
Description: Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
Study NCT02346045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Description: In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~1. After femoral puncture guiding catheter is engaged in renal artery~2. Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~3. 4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed
Study NCT03217708 — intervention group
Intervention type: DEVICE
Intervention: Jawbone UP4
Description: Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugated meningococcal ACWY-TT (vaccine)
Description: One intramuscular dose during the primary vaccination
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
Study NCT00724568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
Study NCT00724568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
Study NCT00724568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
Study NCT00724568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Patients will be treated with Doxil on day 4.
Study NCT04384549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG GROUP
Description: One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
Study NCT04384549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO GROUP
Description: One intradermal injection of 0.1ml NaCl
Study NCT00958243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's 2009 H1N1 Influenza Vaccine (CSL425)
Description: 0.5 mL intramuscular injection on Day 0 and Day 21
Study NCT00958243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's 2009 H1N1 Influenza Vaccine (CSL425)
Description: 0.25 mL intramuscular injection on Day 0 and Day 21
Study NCT00958243 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01103505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ForeseeHome AMD Monitoring Device
Description: Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
Study NCT01171495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theragran-M; Ensure Plus
Description: Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
Study NCT01171495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theragran-M
Description: Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
Study NCT03475784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Description: This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
Study NCT03475784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal fluid therapy
Description: This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
Study NCT01473966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coffee
Description: patients will receive a cup of coffee at room temperature orally twice daily
Study NCT01473966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coffee rectally
Description: patients receive an enema of two cups of coffee at room temperature once daily
Study NCT00966953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study NCT00966953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride toothpaste
Description: Brush twice daily
Study NCT00966953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Brush twice daily
Study NCT00966953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antibacterial plant extract
Description: Brush twice daily
Study NCT03151239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NMN supplement
Description: Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
Study NCT03151239 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention will last at least 8 weeks in the form of two capsules.
Study NCT03931863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4mg
Description: Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Study NCT03931863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Study NCT03931863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100ml normal saline 0.9 percent
Description: Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Study NCT03699644 — intervention group
Intervention type: DEVICE
Intervention: Spectral-Domain Optical Coherence Tomography (SD-OCT)
Description: Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
Study NCT03699644 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
Study NCT03699644 — intervention group
Intervention type: DEVICE
Intervention: Positron Emission Tomography (PET)
Description: Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
Study NCT03699644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmic Examination
Description: Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
Study NCT03699644 — intervention group
Intervention type: DEVICE
Intervention: Fundus Photography
Description: Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
Study NCT00859664 — intervention group
Intervention type: OTHER
Intervention: Genotyping of Cytochrome P450
Description: Genotyping of Cytochrome P450